Alto Neuroscience
Agent48Agent Readiness: 48/100. Above median. Measured by StartupHub.ai. Median 41.Trust60Data Trust: 60/100. Below median. Measured by StartupHub.ai. Median 61.Alto Neuroscience is a clinical-stage biopharmaceutical company developing precision psychiatry medicines for mental health conditions.
About this profileCompany details: from public sourcesFunding: no announced round on fileOwnership: not yet claimed by the companyScores: measured by named tools; each links to its methodOur rules
About
Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing a new generation of precision psychiatry medicines. They use an AI-enabled platform to identify and validate brain-based biomarkers, aiming to match patients with the right Alto drug candidate for depression, PTSD, and other mental health disorders.
Listed competitors
Also in this space
Developing novel therapeutics to restore gut lymphatic function.
Shares HealthTech
Leveraging the adaptive immune system to diagnose and treat disease.
Shares Biotech, HealthTech
Developing engineered biologics to harness the immune system for disease treatment.
Shares Biotech, Drug Discovery
Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.
Shares Biotech, MedTech
Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests for cancer detection, recurrence monitoring, and treatment selection.
Shares Biotech, MedTech
AI-powered platform for personalized cell therapy development and manufacturing.
Shares Biotech, MedTech
Key facts
- Website
- altoneuroscience.com
- Headquarters
- Los Altos, United States
- Founded
- 2019
- Employees
- 86
- Total funding
- $405M (Registered Direct Offering)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 13 Jul 2026 | Registered Direct Offering | $100M | |
| 16 Mar 2026 | Private Placement | $120M | |
| 26 Jan 2023 | Series C | $100M | Lightstone Ventures, Waterman Ventures, Arch Venture Partners |
| 5 Apr 2022 | Series B | $45M | Lightstone Ventures, Waterman Ventures |
| 9 Mar 2021 | Series A | $40M | Lightstone Ventures, Waterman Ventures |
Tech stack
Detected on altoneuroscience.com, last scanned 26 Oct 2026. Run your own scan
- Compliance
- GDPR, CCPA
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- CMS / Builders
- WordPress
- Email provider
- Google Workspace, SendGrid
Alto Neuroscience scores 45. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Alto Neuroscience trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Alto Neuroscience is 60 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Alto Neuroscience raised?
Alto Neuroscience has raised a total of $405M in funding. The most recent round on record is Registered Direct Offering.
How many employees does Alto Neuroscience have?
Alto Neuroscience has approximately 86 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Alto Neuroscience
